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Corruption is a serious threat to global health outcomes, leading to financial waste and adverse health
consequences. Yet, forms of corruption impacting global health are endemic worldwide in public and private
sectors, and in developed and resource-poor settings alike. Allegations of misuse of funds and fraud in global
health initiatives also threaten future investment. Current domestic and sectorial-level responses are fragmented
and have been criticized as ineffective. In order to address this issue, we propose a global health governance
framework calling for international recognition of “global health corruption” and development of a treaty protocol
to combat this crucial issue.
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The impact of globalization on health has been marked
by new and daunting challenges. Though globalization
has enabled advancements in trade, travel, and commu-
nications, it has also facilitated rapid global spread of in-
fectious diseases such as SARS and H1N1/A, requiring a
paradigm shift in global health governance. Yet, the next
global pandemic is not the only challenge facing global
health. A more immediate threat is systemic global
healthcare corruption that adversely impacts both devel-
oped and resource-poor states.
As reported by Transparency International, the scale
and scope of corruption impacting health is immense.
Exact numbers are elusive, but it is estimated billions of
dollars are lost annually due to corruption and fraud in
a global health market estimated to be worth 10% of glo-
bal gross domestic product in 2009 [1-3]. Systematic
corruption in health is also a barrier in meeting the Mil-
lennium Development Goals as it weakens health sys-
tems and delivery [4]. It also disproportionately impacts* Correspondence: tmackey@ucsd.edu
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distribution, and reproduction in any mediumthe vulnerable, including negative health outcomes for
women and children [4].
Importantly, health corruption not only leads to finan-
cial waste of scarce resources, but also has adverse impact
on healthcare access, infrastructures, financing, and social
determinants of health. In addition, health corruption can
severely compromise quality and coverage of services,
leading to price inflation for health service unit costs [5].
Indeed, health corruption at the domestic level
represents a severe impediment to global health efforts
in resource-poor settings and transitional economies.
Corruption can drain resources from already impover-
ished and fragile health systems, precluding access to
life-saving treatment for vulnerable patient populations
[4,6]. With surveys reporting that 80% of individuals in
developing countries have experienced health sector
corruption, these resource-poor populations are dispro-
portionately impacted [4,7,8].
Recent scandals that have plagued global multilateral
health programs have also raised concerns regarding
presence of corruption in global health. Allegations of
corruption and fraud in the Global Fund to Fight AIDS,
Tuberculosis and Malaria (the “Global Fund”) represent
a serious threat to continued funding and support of
global health initiatives. This is particularly concerning
given ongoing funding challenges arising from the recent
global economic crisis [9].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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health corruption impacting global populations points to
a lack of an international framework specifically addres-
sing the wide range of interrelated issues associated with
health-related corruption. Improved global health gov-
ernance is an important first step. Reform to detect and
eliminate forms of corruption that impact health must
be coordinated in order to ensure that health systems
are protected and that global health interventions meet
their full potential.
Global Impact of Domestic Health Corruption
Corruption is defined as the “misuse of entrusted power
for private gain” [10]. In the health setting, it can en-
compass bribery of health professionals, regulators and
public officials; unethical research; diversion/theft of
medicines and medical supplies; fraudulent or overbill-
ing for health services; absenteeism; informal payments;
embezzlement; and corruption in health procurement
[4,10,11]. Though many of these activities are domestic-
ally-focused, they nevertheless impact global health out-
comes. Domestic corruption may have global results due
to interconnectedness of domestic and global health fi-
nancing, a globalized drug supply chain, health worker
migration, and shared global health security.
In combination with the reality that criminal activities
can easily impact and move across geopolitical borders
affecting multiple states/organizations, health corruption
presents significant challenges for detection and enforce-
ment. The broad infiltration of corruption, diversity of
illicit acts, and multitude of stakeholders involved (often
with limited or indirect accountability) adds to health
system complexity, existing information asymmetry, and
uncertainty in health markets, with developing countries
particularly vulnerable [4,10].
Beyond developing countries, domestic corruption is
also endemic in developed and emerging economies. For
example, 5-10% of USA public sector health expendi-
tures are lost to fraudulent overbilling [2]. Recent
reports in the USA of $4 billion in recoveries in enforce-
ment actions, a $163 million indictment against an orga-
nized crime enterprise for fraudulent billing, and other
cases highlight the near universality of domestic level
health corruption and fraud [12,13]. As well, 5% of the
Cambodian health budget is lost to corruption within
the central government, and 56% of Russian Federation
total health expenditures are “informal” payments [2].
The global drug supply chain also provides an illustra-
tion of how lack of regulatory harmonization can lead to
forms of global health-related corruption [14,15]. Health
systems in developing regions and emerging markets
that lack transparency, regulatory control, and adequate
law enforcement can result in public and private sector
extortion and bribes that enable production and sale ofcounterfeit drugs [14,15]. As a result, counterfeit medi-
cines can be exported to other global markets, resulting
in documented patient death and morbidity, pathogen
resistance and decreasing drug effectiveness, waste in
resources for pharmaceutical products and services, and
lack of safe access to essential drugs [14-16].
Note that health corruption also extends to legitimate
corporate entities. For example, corruption allegations
against multinational pharmaceutical and medical device
companies such as Johnson & Johnson, Merck, Eli Lilly,
and Medtronic have surfaced involving bribery of physi-
cians and health officials overseas. As pharmaceutical
companies push to gain entry into emerging markets,
competition gives rise to corrupt practices and have
been prosecuted as potential violations under USA and
UK foreign anti-bribery laws [17]. Reflecting this trend,
recently the world’s largest drug manufacturer, Pfizer,
agreed to pay a fine of more than $60 million to settle
violations of USA anti-bribery laws for improper pay-
ments to healthcare professionals in a number of
countries including China, Russia, Bulgaria, Croatia,
Kazakhstan and Italy [18].
This broad spectrum of domestic level health cor-
ruption that has a global impact encompasses coun-
tries at all levels of development, spans various types
of illicit activities, and includes both public and private
actors. (See Figure 1) The broad scope of the problem
necessitates development of systems of international
cooperation and governance in order to mount a
comprehensive solution.
Corruption in Global Health Interventions
Large scale, multilateral global health programs also
present new opportunities for health corruption. Alleged
domestic corruption in developing countries receiving
aid through the multibillion-dollar Global Fund has re-
cently shaken public trust in global health initiatives and
financing [19]. Yet these are not the first allegations of
corruption in the Global Fund or other multilateral glo-
bal health projects.
For example, corruption was discovered in 2008 in
five multimillion-dollar health projects financed by the
World Bank in India. The program was aimed at
combating tuberculosis, malaria and HIV/AIDS. Inves-
tigation uncovered procurement corruption, including
bid-rigging and bribery [20]. Further, investigators dis-
covered substandard HIV/AIDS testing kits, which
may have produced incorrect results and exacerbated
disease spread [20]. Yet, Indian public officials have
expressed a level of acceptance regarding the corrup-
tion allegations, commenting it is systemic in India
[20]. India is also a known for having a large informal
health sector susceptible to corruption and informal
payments for health services [7,20].
Figure 1 Examples of health corruption types and scopes.
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For example, corruption in Uganda involving Global
Fund disbursements of $45.3 million in 2006 revealed il-
legal acts by public officials, government ministers, and
community health workers [21]. Several actors
defrauded the Global Fund, leading to the temporary
grant suspension and interruption of patient antiretro-
viral therapy with adverse consequences for its recipients
[21]. Corruption was uncovered by a whistleblower, not
internal evaluators, and later verified by an independent
auditor and national judicial commission that detailed
misappropriation, forgeries, nepotism, and lack of ac-
countability [21].
Other findings show continued corruption in these
initiatives. For example, the Global Fund’s own inde-
pendent audit unit and later the Associated Press
revealed $34 million in Fund grants that may have been
misused in Djibouti, Mali, Mauritania, and Zambia [19].
This includes allegations of forged documents, improper
bookkeeping, donated drugs diverted and sold on the
black market, and a range of 30-67% of funds reportedly
misspent [19]. This prompted some donor countries
(e.g., Germany, Ireland, Sweden) to announce they
would be suspending support of the Global Fund in light
of corruption policy concerns [22,23].
Concerns also extend to the U.N. Development Pro-
gram itself, which manages half the Global Fund’s spend-
ing. It refused to share internal audit reports citing its
own governance rules on audit controls and disclosure.
[19,22] This led to increased scrutiny regarding the in-
tegrity of the Fund, further damaging its credibility.
In response, the Global Fund announced it would be
restructuring its auditing procedures and establishing
additional measures to enhance financial oversight [24].Coincidentally, the Global Fund recently announced it
was suspending future grant funding due to lack of
funds following the aftermath of fraud disclosures [25].
The consequences of these allegations make it clear
that forms of corruption in global health programs
continue to represent a severe risk to progress in
these important interventions as donors and the pub-
lic scrutinize funding use and management. This is
despite the fact that the amounts allegedly stolen rep-
resent less than 1% of total amounts disbursed by the
Global Fund [25].
Suggested Policy Approaches
In response to the threats posed by forms of domestic
and international health corruption, creative global
health governance policy solutions should be explored.
Individual state-based legal and institutional reform
measures that have been proposed include improving al-
location, monitoring, auditing and health expenditure
tracking; adopting codes of conduct and ethics; and
developing rules to increase transparency [5,10]. How-
ever, a lack of a comprehensive, internationally coopera-
tive framework specifically addressing health corruption
on a global level undermines the effectiveness of these
independent efforts.
To address these corruption challenges, we propose a
global health governance approach. This would be based
upon creating international consensus and recognition
of the concept of “global health corruption.” Creating
recognition of an overarching definition coupled with
development of an internationally binding treaty proto-
col and a governance framework can lead to cooperation
and potential for harmonized laws and regulations to ef-
fectively combat global health corruption (see Table 1).
Table 1 Key Points of Global Health Anti-Corruption Framework





of authority, resources, trust or power for
private or institutional gain that has
adverse effects on regional, local, or
international health systems and/or that
negatively impacts individual patient and/
or population health outcomes.”
Establishes an internationally recognized
definition and draws needed attention
to the unique risks of health-related
corruption
International community and
input from all relevant
stakeholders (e.g. public health
agencies, law enforcement,
regulators, judicial system, civil





Development of an international binding
treaty protocol on global health
corruption and establishing the necessary
global health governance framework
Implements definition under an
existing international treaty and
establishes infrastructure for global
corruption framework






Model Acts System: Development of
Model Acts system of core anti-
corruption definitions and requirements
for individual states to implement
with certain flexibilities
Development of a model system for
states to follow in developing their
own domestic systems and aids in
harmonization
Signatories to Protocol in
consultation with domestic
stakeholders
Domestic and Regional Corruption Tools:
Assessment of inclusion of existing
domestic anti-corruption tools that
have had success
Examines existing enforcement tools
that have curbed domestic level
health corruption
Governance structure of protocol
(e.g. conference of state parties,
other developed governing body)
Useful International Tools and Systems:
Assessment and active inclusion of




Assesses existing tools developed by
international organizations aimed at
addressing global health system
corruption
Governance structure of protocol
(e.g. conference of state parties,
other developed governing body)
Governance System: Development and
implementation of dynamic global health
governance structure to address global
health corruption flexible enough to deal
with diverse forms of corruption in
different settings
Governance system flexible enough
to be tailored to domestic and global
health system needs. Should be
comprehensive including components
of protocol implementation, financing,
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Definition of “Global Health Corruption”
A crucial first step in addressing global health corrup-
tion is establishing international recognition and consen-
sus of this specific type of corruption while emphasizing
the importance of developing anti-corruption tools in
health policy and capacity building goals [4]. Though the
general concept of “corruption” has been recognized in
the U.N. Office on Drugs and Crime’s (“UNODC”) 2003
U.N. Convention against Corruption (“UNCAC”), a le-
gally binding anti-corruption instrument, unique chal-
lenges created by both domestic and global health
system corruption impacting population-based health
have not been delineated [26].
In response, the concept of global health corruption
should be expressly defined, discussed, and adopted
through an international legally binding framework
employing partnership with the World Health
Organization (WHO) and the UNODC. This can be
accomplished through consultative meetings and devel-
opment of a Global Health Corruption Treaty Protocol
to the UNCAC, with ongoing and active participation ofWHO to add provisions specifically addressing health.
We believe an effective working definition of global
health corruption could start as the: “misappropriation
of authority, resources, trust or power for private or in-
stitutional gain that has adverse effects on regional, local,
or international health systems and/or that negatively
impacts individual patient and/or population health out-
comes.” This definition should include the varying forms
of corruption occurring both at the domestic and global
program system level, as both forms of corruption can
have an impact on global health.
This standard definition can provide the basis for stra-
tegic efforts to coordinate cross-border, regional and
international actors to detect and prosecute criminals in
concert with existing or future domestic and regional
laws that recognize the important differentiation of gen-
eral corruption and corruption impacting health. This
can result in individual countries enacting domestic laws
that are harmonized internationally to allow law enforce-
ment to coordinate global anti-corruption strategies for
more effective prosecution. This can lead to develop-
ment of best practices, with defined subsets of forms of
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nerabilities in health corruption, development of efficient
financing mechanisms and judicial systems, and mini-
mum requirements for transparency, enforcement and
prosecution.Model Acts System
To implement this governance system, a “model act” ap-
proach, similar to USA that allows adoption of model
clauses and harmonization by individual states, may be
an efficient strategy. This would allow WHO-UNODC
to build on agreed upon global health corruption
definitions but tailor them for cultural and infrastruc-
tural differences, allowing more effective adoption by
individual countries sensitive to the local environ-
ment. Components could include model requirements
for public and private sector policies on disclosure,
auditing, procurement, drug supply, and payments to
healthcare professionals.Domestic and Regional Corruption Tools
Developed country anti-bribery laws may also serve as
potential enforcement tools that can be assessed for in-
clusion in a global health corruption framework. Laws
such as the USA Foreign Corrupt Practices Act and UK
Anti-Bribery Act prohibit corporations and individuals
based in these countries from bribing public officials in
other countries and engaging in other forms of corrup-
tion; they have been successful in at least some health
sector prosecutions [17,18].
Other national laws, such as the USA Anti-kickback
Statute and the False Claims Act, impose both civil and
criminal fines for the submission of false claims and for
providing forms of remuneration to healthcare profes-
sionals for referrals for services covered under national
healthcare programs [27]. These laws employ incentive
and payment schemes that reward whistleblowers who
report illegal activity and have resulted in record-
breaking fines against criminal and industry actors
[27]. Such enforcement tools could be incorporated
into other national healthcare programs to improve
enforcement and prevention, and modified so that
recovered amounts are earmarked for public health fi-
nancing/system strengthening. Collectively, these do-
mestic laws currently rely upon developed country
enforcement and could be more effective if they had
global or regional coverage.
Further, domestic and regional efforts such as the UK’s
National Health System anti-fraud unit and the European
Healthcare Fraud and Corruption Network could also be
considered. These represent models for tailored anti-
global health corruption systems that may be scaled up for
increased more regional/global coverage.Useful International Tools and Systems
As part of enhanced governance efforts, WHO-UNODC
should utilize existing research and guidance on corrup-
tion in health, including methods, tools and good prac-
tices as developed by the United Nations Development
Programme (“UNDP”) [4]. These strategies, include an
emphasis on prevention, broad-based partnership and
participation with various stakeholders and sectors,
whistleblowing mechanisms, and creating incentives and
disincentives for good and bad behavior respectively [4].
These efforts can include integration of WHO’s own
programs on corruption, including diagnostic and risk
assessment tools and the WHO Good Governance for
Medicines Programme [4]. They should also integrate
World Bank tools such as the Detailed Implementation
Review, a proactive diagnostic tool used by the Bank to
evaluate projects for indicators of fraud and corruption
using forensic accounting and fraud investigation techni-
ques that assess and detect the risk of fraud and corrup-
tion. These tools, along with front-line tools developed
by USAID, specifically target multilateral global health
programs and should be incorporated [4,28]. By coordin-
ating these divergent efforts into a central framework,
better policy coherence and cooperation can occur
across agencies/platforms.
Governance Systems
Recognizing that there is no “one size fits all” approach
in establishing a comprehensive framework to deal with
all forms of global health corruption, careful attention
should be given to programmatic differences between
domestic versus global health systems. Hence, vertically
integrated global health initiatives spanning the scope of
multiple, international stakeholders focused on individ-
ual diseases need to be addressed uniquely within the
context of susceptibility to corruption. Similarly closed
national health systems that are not primarily funded by
international health or development assistance and are
primary-care focused need to be assessed differently
from their global health system counterparts.
Fortunately, global governance models are available
for guidance. Using the UNCAC experience, global
governance approaches to corruption can include WHO-
UNODC member creation of formal and binding sys-
tems. This includes establishing a strategy for global
health corruption protocol implementation, anti-
corruption system financing, and overall health system
strengthening. This can be accomplished by providing
technical assistance to member states, developing model
policies and tools for anti-corruption, identifying “at-
risk” countries, exploring innovative financing mechan-
isms (e.g., funding through allocation of a percentage of
anti-corruption fines/recoveries) and coordinating efforts
with other multilateral and bilateral development, health,
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sector [29]. These efforts can also be coupled with inter-
national initiatives to improve aid effectiveness, by inte-
grating developed anti-corruption strategies into efforts
of the Paris Declaration on Aid Effectiveness and related
forums.
At a minimum, these governance systems should in-
volve multiple interventions and include: (1) transpar-
ency and audit policies; (2) a common framework for
corruption monitoring and evaluation of public health
programs and funding; (3) Codes of Conduct for public
and private sector actors; (4) minimum standards for
member state laws to specifically prevent and prosecute
health-based corruption; (5) health financing improve-
ments to curtail the need for an informal health sector;
(6) a centralized surveillance and data repository sys-
tem to report and investigate global health corruption;
(7) multilateral processes to freeze proceeds from corrup-
tion and aid in recovery of diverted assets; and (8) com-
mitment to earmark portions of seized assets to fund and
develop these anti-corruption systems among members.
This dynamic and comprehensive “global health anti-
corruption” framework can build on existing and future
best practices, as well as examine previous corruption
case studies to determine appropriate strategies that are
sensitive to domestic or regional limitations. Though
these policies may results in some additional costs and
require administrative resources to implement, they are
nevertheless crucial in protecting and obtaining the ben-
efits from public health investments, enhancing health
system strengthening, and maintaining public trust in
global health interventions.
Potential Benefits
The potential benefits of the proposed global health gov-
ernance framework could be significant, starting with
global recognition regarding the unique risks of global
health corruption and its adverse impact on societies
worldwide.
Importantly, this strategy can assist in addressing cor-
ruption both on a global and domestic level. Beyond co-
ordinating domestic and international law enforcement
efforts, more focused strategies to prioritize rapid review
of health projects and systems that are most susceptible
to corruption and have the greatest potential negative
impact on health outcomes should be addressed imme-
diately [4]. As an example, forms of pharmaceutical sec-
tor corruption that enable production and consumption
of dangerous counterfeit medicines and represent an im-
mediate patient safety threat can be prioritized in global
anti-corruption efforts.
In addition, anti-corruption actions can be strategically
targeted for diverse domestic populations by disseminating
community-based monitoring tools addressing differentforms of health corruption endemic in particular setting
(e.g., border and migrant health). As well, proactive re-
gional risk assessment can allocate resources to popu-
lations most affected by global health corruption.
Such a “top down/bottom up” approach can allow for
flexibility of a dual global and domestic approach to
combating global health corruption, ensuring better
accountability, transparency, and importantly, effective
use of anti-corruption investment.
Summary
Global health corruption remains a serious, ongoing,
and under recognized threat to global health progress.
Unfortunately, the world’s most vulnerable shoulder
much of this life-and-death burden. Further, recent glo-
bal health program scandals serve to emphasize the need
for progressive and global reform.
Under Article 12 of the International Covenant on
Economic, Social, and Cultural Rights, every human has
a fundamental right to the highest attainable standard of
health [30]. Global health corruption undermines this
fundamental right. Domestic, international, public and
private entities must join together to ensure that health
equity is given true weight. This requires a commitment
to collectively address global health corruption so that
benefits of global health efforts inure to the populations
they are intended for.
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